Redox resetting of cisplatin-resistant ovarian cancer cells by cisplatin-encapsulated nanostructured lipid carriers

Aim: To sensitize cisplatin (Cis)-resistant ovarian cancer cells toward Cis using Cis-loaded nanostructured lipid carriers (CisNLCs). Materials & methods: CisNLCs were synthesized and characterized using dynamic light scattering, Fourier transform IR and x-ray diffraction (XRD). Sensitivity of PA-1 and CaOV3 cells to Cis and its biotoxicity were assessed. Further, expression of the Cis-resistance markers GSTPi and ATP7B, and apoptotic markers Bax, Bcl2 and Cas9 were quantified by real-time PCR. Results: The size of synthesized CisNLCs was approximately 179.3 +/- 2.32 nm and surface charge was -33.9 +/- 1.47 mV. IC50 was 210 mu g/ml in PA-1 and 500 mu g/ml in CaOV3. CisNLCs modulated reactive oxygen species levels in CaOV3 cells. Reduced GSTPi and decreased Cis efflux via ATP7B sequestration caused Cis to accumulate in cytoplasm, thereby augmenting apoptosis in cells. Conclusion: CisNLCs sensitize CaOV3 by redox resetting, indicating their immense therapeutic potential.

Automated summary

The study aimed to sensitize cisplatin-resistant ovarian cancer cells towards cisplatin using cisplatin-loaded nanostructured lipid carriers. The results showed that the synthesized cisplatin-loaded nanostructured lipid carriers successfully enhanced the sensitivity of the resistant cancer cells by modifying reactive oxygen species levels and increasing apoptosis in the cells.